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Intravenous iron for the treatment of predialysis anemia. This reduced cardiac output, and improvement in exercise
article, based on our own studies and those of others, presents tolerance and exercise-induced ST segment depression
evidence to show that the anemia of chronic renal failure in on ECG [2, 8]. Treatment of the anemia with EPO inthe predialysis period is, to a significant extent, caused by iron
dialysis patients was also associated with a 20% lowerdeficiency and can be improved in most cases by the administra-
mortality at one year as compared with a control grouption of intravenous (i.v.) but not oral iron. We estimate that
in approximately 30% of all predialysis patients with anemia, that did not receive EPO [9, 10]. It is reasonable to
a target hematocrit (Hct) of 35% can be reached and main- assume that the detrimental effects of anemia, as well
tained by giving i.v. iron alone without exceeding currently
as the beneficial effects of its treatment, would apply toacceptable limits of serum ferritin (500 mg/liter) or the percent-
predialysis patients as well. Indeed, a prospective studyage of iron saturation (40%). If, in addition, subcutaneous
erythropoietin (EPO)—usually in only low doses—is added, of predialysis patients has revealed that anemia is an
the combination has an additive effect on the Hct response, independent risk factor for LVH [4], and another study
and almost all anemic predialysis patients can reach and main- has found that predialysis patients have the same regres-tain the target Hct of 35% over a one-year period. Therefore,
sion of LVH and the same reduction in cardiac outputthe advantage of maintaining adequate iron stores with i.v.
after EPO therapy that is seen in dialysis patients [11].iron is that if EPO is needed, lower doses will be required to
achieve the target Hct than if EPO were used alone. This not In another recent study, CHF was present before onset
only avoids the high cost of EPO therapy but also its associated of dialysis in 34% of patients with untreated anemia but
side-effects, especially hypertension. Using Venofer, a ferric
in only 5% of patients in whom the anemia was treatedhydroxide sucrose complex, as our i.v. iron supplement, we
with EPO [5]. It is daunting to think that so many of thehave seen no anaphylactic reactions in over 20,000 infusions
over a four-year period in 360 hemodialysis, 123 predialysis, cardiac abnormalities that are so prevalent at the time
and 58 peritoneal dialysis patients. dialysis begins, and so damaging to the patients chances
of survival and quality of life before and while on dialysis,
could have been prevented if a more aggressive approach
Diseases of the heart are the most frequent causes of had been taken to the treatment of the anemia years
death in patients with end-stage renal disease [1]. In earlier [1].
patients on maintenance dialysis, approximately 40% to
50% of all deaths are attributed to lethal cardiac events
IRON DEFICIENCY IN PREDIALYSIS CRF:[2, 3], and the rate of cardiac mortality is up to 20 times
A MAJOR CONTRIBUTOR TO RENAL ANEMIAhigher than an age- and sex-related normal population
[3]. In predialysis chronic renal failure (CRF) [4, 5] and There is growing evidence that iron deficiency is a
in dialysis patients [6, 7], in addition to the usual treatable common and important cause of the anemia associated
risk factors that contribute to heart disease such as hyper- with CRF. Several studies of the bone marrow in anemic
tension, hyperlipidemia, smoking, and diabetes, anemia predialysis CRF patients have revealed that a vast major-
must now be added [1]. In patients on dialysis, anemia ity of these patients have evidence of reduced iron stores,
is an independent risk factor for the development of left even when iron indices in the blood are normal [12–14].
ventricular hypertrophy (LVH) and dilation, de novo We recently demonstrated that the majority of anemic
and recurrent congestive heart failure (CHF), and mor- predialysis CRF patients, having remained anemic de-
tality [6, 7]. Conversely, treatment of renal anemia with spite oral iron supplementation and not receiving EPO,
erythropoietin (EPO) in dialysis patients can cause re- will respond to the administration of intravenous (i.v.)
gression of LVH, reduction in left ventricular volume, iron with an increase in hematocrit (Hct) of a mild to
marked degree [15]. In that study, 200 mg of elemental
iron was administered i.v. as a ferric hydroxide sucroseKey words: iron deficiency, cardiovascular disease, end-stage renal dis-
ease, dialysis. complex (Venofer-Vifor Int., St. Gallen, Switzerland) ev-
ery month for five months (total dose 1000 mg). The mean 1999 by the International Society of Nephrology
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Hct increased by an average of 1.9 vol% by one month duodenal ulcers [35]. The bleeding tendency seen in ure-
mia [37] may also contribute to the bleeding and subse-after the last dose. Twenty-two of the 33 patients showed
a mean increase of 2.9 vol% (some of them increasing quent iron loss. The frequent use of low-dose aspirin for
the commonly associated cardiovascular (CV) diseasesby more than 10 vol%). We could find no parameters,
including serum ferritin or percentage iron saturation can increase gastrointestinal blood loss even further
[38, 39]. Patients with proteinuria, especially in the neph-(serum iron/serum total iron binding capacity 3 100),
that could serve as predictors of the patients’ response. rotic range, can lose up to 1 mg of iron in the urine per
day [40].
In one study in HD patients [41], even though oral
CAUSES OF IRON DEFICIENCY
iron was absorbed normally, its incorporation into redIN PREDIALYSIS CRF
cells was both delayed and less than normal so that the
There are many reasons that predialysis CRF patients Hct did not increase despite three months of oral iron.
may develop an iron-deficiency anemia. Simple anorexia, On the other hand, the mean Hct increased by 4.1 vol%
caused by CRF, could result in reduced iron intake. Low- when an i.v. iron preparation was used. This underlines
protein diets reduce the amount of animal protein that the second problem in iron deficiency, the so-called func-
is eaten. This can cause not only a quantitative fall in tional iron deficiency, in which the iron stores may be
iron intake but also a fall in the percentage of the in- normal, yet there may be poor availability and use of
gested iron that is absorbed, as the percentage of iron stored iron. In addition to all of these problems of ab-
absorbed from animal protein is much higher than the sorption and use of oral iron, oral iron supplementation
percentage absorbed from vegetable protein [16], and it may be unsuccessful because of the poor compliance
is the animal sources of protein that are primarily re- associated with its use. This is due not only to the side
duced when low-protein diets are prescribed. effects caused by oral iron preparations but also to the
Many studies of patients on hemodialysis (HD) [17– difficulties CRF patients have in taking medications as
19], on peritoneal dialysis (PD) [20, 21], or in the predial- prescribed [42].
ysis period [22, 23] have found evidence of reduced intes-
tinal iron absorption, as have studies in uremic rats [24].
USE OF ORAL IRON PREPARATIONSAt least part of this reduced absorption could be ex-
IN PREDIALYSIS PATIENTSplained by the intestinal mucosal changes seen in uremia.
Moderate to severe histological changes, including re- Because of the problems of iron absorption mentioned
duction of villous height, increased crypt depth, and in- earlier here, it is not surprising that oral iron supplemen-
filtration of inflammatory cells, as well as functional tation has often failed to improve the anemia in HD
changes such as decreased activity of dipeptidases and patients whether they are on EPO [43, 44] or not [14,
increased activity of disaccharidases, are commonly seen 41, 45], whereas i.v. iron has improved anemia in both
in the small intestines of patients with CRF [25, 26]. of these groups [13, 14, 41, 43–46]. Similarly, oral iron
Indeed, in one study, 29% of uremic patients had in- in the predialysis group has failed to improve the anemia
creased fecal fat [25]. One possible cause of these abnor- when give alone [15, 47] and is associated with progres-
malities could be the alteration in the bacterial flora of sive iron deficiency when used with EPO [48–50]. On
the intestine that takes place in CRF [27]. The bacterial the other hand, as mentioned earlier, we have shown that
overgrowth seen in CRF could cause the overproduction i.v. iron has improved the anemia in many predialysis
and accumulation of potentially toxic substances that patients when oral iron has failed, even without the use
could damage the mucosa [28]. Calcium and aluminum of EPO [15]. Surprisingly, this subject—the role of i.v.
phosphate binders may also reduce iron absorption [29– iron either alone or in combination with EPO in predial-
32], as can histamine-2 blockers [33]; all of these are ysis patients—has received little attention.
used frequently in CRF patients.
Gastrointestinal bleeding appears to be very common
EFFECT OF INTRAVENOUS IRON AND LOW-in CRF, and this may contribute to the iron deficiency
DOSE EPO ON PREDIALYSIS RENAL ANEMIAas well. A positive test for occult blood was found in
17% [34] and in 18.8% [35] of predialysis patients, 6.3% In a more recent study (submitted for publication),
we administered 200 mg of i.v. Fe once weekly for fiveof HD patients [35], and 7.3% of PD patients [35]. These
findings are consistent with those of others [36], who weeks to 90 CRF patients with moderate to severe CRF.
In half of them, simultaneous with the i.v. Fe, we alsofound a mean fecal blood loss of 3.15 ml/day in predial-
ysis patients and 6.27 ml/day in HD patients, greater gave 2000 IU EPO subcutaneously once weekly for each
of the five weeks. In both groups, the mean serum ferritinthan the 0.82 ml/day found in normal volunteers. The
most common lesions that were seen in uremic patients and percentage Fe Sat at onset were similar (approxi-
mately 160 mg/liter and 20%, respectively), values thatwith bleeding were erosive gastritis or duodenitis and
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some would consider to be within the normal range. previous study of predialysis patients [15], one of 34
patients developed sweating and nausea after only a fewWith the combination of i.v. iron and EPO, 43 out of 45
(95.6%) had an increase in the Hct, the mean increase drops of i.v. iron without any drop in BP or tachycardia.
The iron was stopped, and the patient felt better withinbeing 4.54 6 2.64 vol%, and 18 (40%) actually achieved
the target Hct of 35%. With the i.v. Fe alone group, 35 five minutes. No further i.v. iron was given. Side effects
with iron sucrose have been reported when the agentout of 45 (77.8%) had an increase in the Hct, the mean
increase being 2.74 6 2.72 vol% and 13 (28.9%) actually has been given very rapidly or in very high doses but
were very uncommon when lower doses were given overachieved the target Hct of 35%. Thus, the combination
of EPO and i.v. Fe had an additive effect. These patients a longer period of time [54, 55]. Perhaps the low preva-
lence of side effects in our patients is related to the factwere then followed up for one year. Intravenous Fe and
EPO were administered as necessary to maintain a Hct that we gave relatively low doses over a prolonged period
of time. In addition to the 123 predialysis CRF patientsof 35%, as well as to maintain the serum ferritin and
percentage Fe Sat below what was considered to be the who have received doses of 200 mg i.v. iron sucrose in
our two predialysis studies, we have given 100 mg of theupper tolerable limits (serum ferritin of less than 500
mg/liter and percentage Fe Sat less than 40%). All but same preparation i.v. on the average of twice monthly
to 360 HD patients over the past four years. We haveone achieved a Hct of 35% or more. On the average,
the patients required 148 mg of i.v. Fe per month. The also given the agent every few weeks to 58 PD patients
in a dose of 200 mg. Altogether, we have given a totalmean weekly subcutaneous EPO dose needed to achieve
this Hct was 1986 IU. This is in contrast to other predial- of more than 20,000 infusions of i.v. iron without experi-
encing a single anaphylactic reaction. We administer theysis studies in which only oral iron supplementation was
given to patients receiving EPO in order to achieve and i.v. iron as an infusion in 150 ml normal saline over 60
minute (after a test dose). A similar low record of adversemaintain a Hct of 33% to 35%. In these studies, mean
effects during HD has been seen with iron gluconate [56]doses of approximately 8000 to 9000 IU EPO/week were
and iron polymaltose [57] when administered slowly. Onneeded [49, 50]. Thus, it seems that i.v. Fe is a major
the other hand, anaphylactoid reactions (defined as anyadjuvant therapy in the correction of the anemia of predi-
dyspnea, wheezing, chest pain, hypotension, urticartia,alysis patients and, in the vast majority of cases, allows
or angiodema) occurred in 1.7% of HD patients receiv-the target Hct of 35% to be reached with relatively small
ing iron dextran [58]. Although no comparative study ofdoses of EPO.
the different preparations has been published, there is
other evidence that also suggests that it is the type of
IMPLICATIONS OF THE USE iron preparation and not the administration of i.v. iron
OF INTRAVENOUS IRON per se that causes these reactions. In a study of nine
IN PREDIALYSIS PATIENTS patients who had serious reactions to i.v. dextran, eight
In the predialysis period, the usual approach to the had no such reactions to iron gluconate [59], and the
treatment of anemia at this time is to give EPO [51], ninth patient had only mild and tolerable paresthesias,
which is administered subcutaneously. The use of EPO, which did not require stopping the iron.
however, has caused concern because of its tendency to
Risk of renal damageraise the blood pressure (BP) in predialysis patients [52].
This increase in BP may be more prevalent than is gener- Our predialysis patients were followed for at least 12
ally considered because it may not be detected if only months after having received the i.v. iron and EPO, and
casual BP, not 24-hour ambulatory BP, is measured [11]. we have found no alteration in the degree of urinary
There is the added concern that EPO therapy may hasten protein after the administration of the 1 to 2 g of i.v.
the deterioration of renal function. Although most stud- iron. In addition, there was evidence of a slowing in the
ies have found no evidence for this [53], in some patients rate of renal functional deterioration as judged by the
there is a suggestion that renal function worsens with slope of the liters/creatinine. Indeed, one study recently
EPO treatment [49]. Because of these concerns, as well found that improvement of the anemia may retard the
as the cost, it would seem desirable to reduce EPO use progression of CRF [60]. Nevertheless, there is concern
to a minimum in predialysis patients. about the toxic effects of iron on the kidney. Iron accu-
mulates in renal tubular cell lysosomes in several models
of renal disease and may cause proteinuria or deteriora-POSSIBLE NEGATIVE ASPECTS
tion in renal function [61]. Iron loading in humans withOF IRON THERAPY
thalassemia and other chronic anemias can cause in-
Acute allergic or hypersensitivity reactions creased glomerular and tubular cell iron levels [62]. In
We found no side effects associated with the use of a group of patients with prosthetic heart valves accompa-
nied by severe iron overload due to hemolysis, proximalthe i.v. iron in the study described earlier here. In our
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tubular atrophy and interstitial fibrosis were seen in that which was found in our study. In addition, the ac-
companying use of EPO, even in small doses, wouldthose with severe but not with mild-to-moderate iron
overload [63]. Patients with thalassemia who received reduce the risk of iron overload and its complications
even further. In the recent Amgen Study [73], HD pa-many blood transfusions over several years were found
to have a reduction in urinary concentrating ability [64]. tients with CHF or ischemic heart disease who achieved
a normal Hct (mean 42%) with EPO and i.v. iron hadIn all these studies in humans, it is possible, however,
that the renal changes could have been due to factors more CV events than those with a lower Hct (mean
30%). The group with the higher mean Hct also receivedother than iron overload itself. In a recent review of 433
cases of hereditary hemochromatosis, renal disease was more i.v. iron (although the serum ferritin and percent-
age transferrin saturation was no different in the twonot reported in even one instance, despite the fact that
the mean serum ferritin and transferrin saturation was groups). Whether the i.v. iron contributed to the increase
in CV events is uncertain. In our predialysis patients, wemuch higher than in our study [65]. Thus, it seems un-
likely that i.v. iron in the doses we used causes any aimed for a target Hct of 35%.
worsening of the renal disease.
Liver damage
Blood pressure changes We found no evidence of alteration in liver function
in any of our patients. The doses of i.v. iron that we usedIn this study, the mean BP before or after the first
and second study did not increase. Two patients required were quite small. Although our study was short term,
even when greater doses of iron, as iron dextran, averag-an slight increase in the dose of antihypertensive medica-
tions. In our previous study [15], we found that, despite ing 2 to 9 g per year, have been given for up to 10 years
in HD patients, associated with a mean serum ferritinan improvement in the Hct, there was a rise in BP in
only four of 33 predialysis patients over a six-month of 944 mg/liter and a mean iron saturation of 44%, the
period, although this increase was only slight and easily mean iron concentration in the liver was only 345 mg
controlled. Although it has been shown in one study that per 100 mg dry weight (normal 30 to 140) [74], whereas
merely increasing the Hct by administration of blood the levels at which liver damage from iron load is seen
can raise the BP of HD patients [66], others have not are over 2000 mg per 100 mg dry weight [75]. It is unlikely
found this increase [67]. In PD patients, a spontaneous therefore that the i.v. iron in the amounts given here
increase in Hct has also not caused an increase in BP would cause toxic liver effects. The use of small doses
[67]. Although the use of EPO is frequently associated of EPO would, in any case, reduce liver iron levels.
with a worsening of the BP in predialysis patients [11],
Lipid peroxidationas it is in dialysis patients [53], the improvement of the
anemia in EPO-treated patients after the addition of i.v. High doses of iron can lead to increased peroxidation
iron has not been associated with an increase in casual of low-density lipoprotein (LDL), which could contrib-
BP [68]. Similarly, the increase in Hct after androgen ute to a worsening of atherosclerosis [76]. Although oxi-
therapy of renal anemia is not associated with an increase dized LDL was found to be elevated in one study of HD
in BP [69]. This is consistent with a recent study of patients who received i.v. iron but not those who received
uremic rats in which blood transfusions increased the EPO [77], we did not find evidence for increased oxidized
Hct without increasing the BP. On the other hand, EPO LDL in 12 predialysis patients who had received 1 to
increased the BP whether or not the anemia improved 2 g of i.v. iron over a four-month period (unpublished
[70]. Studies in humans have also found that EPO can observations).
raise the BP independently of the degree of rise of the
Increased susceptibility to infectionHct [52]. Thus, the use of i.v. iron, by reducing the total
requirement of EPO, may avoid the increased BP seen There is some evidence that iron excess might lead to
with higher dose EPO. increased susceptibility to infection [73, 78, 79]. We
found no evidence of this in our patients; however, our
Heart disease follow-up was short, our patient numbers small, and we
Although it has been suggested that the risk of coro- had no control group.
nary heart disease increases with increasing body iron
stores, the vast majority of epidemiological data, includ-
LABORATORY PARAMETERS PREDICTIVEing prospective, cross-sectional, case control, and au-
OF DEGREE OF HEMATOLOGICAL RESPONSEtopsy studies, have failed to support this hypothesis [71].
In our previous studies in predialysis [15] and dialysisAlthough dilated and restrictive cardiomyopathy have
[46] patients, we found that neither the serum creatinine,been found in iron overload states [72], this has occurred
serum iron saturation, nor serum ferritin predicted theonly after many years of iron overload and where the
serum ferritin and iron saturation were much higher than Hct response to either iron, EPO, or the combination.
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In this study, the only initial parameters that correlated in most cases, and in approximately 30% of cases, this
treatment alone will allow a target Hct of 35% to bewith the change in Hct were in the group who received
i.v. iron alone. In this group, the change in Hct was reached and maintained. If a combination of EPO, usu-
inversely correlated with the initial serum creatinine and ally in low doses, and i.v. iron is used, this target Hct
to the initial percentage Fe Sat. We also measured serum can be reached in almost all cases because the two agents
EPO and transferrin receptor levels before the i.v. iron have a significant additive effect.
and combination i.v. iron and EPO therapy, and they
failed to have any value in predicting the Hct response ACKNOWLEDGMENTS
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usually recommended for anemic patient predialysis with
serum ferritin values above 100 mg/liter and percentage
APPENDIXtransferrin saturation above 20% is to start EPO instead
of first attempting to increase the iron stores further [51]. Abbreviations used in this article are: BP, blood pressure; CHF,
congestive heart failure; CRF, chronic renal failure; CV, cardiovascu-Perhaps this avoidance of iron therapy is due to the
lar; EPO, erythropoietin; Fe Sat, iron saturation; Hct, hematocrit; HD,unconfirmed belief that these values, in CRF patients, hemodialysis; i.v., intravenous; LDP, low-density lipoprotein; LVH,
reflect adequate iron stores and iron availability, yet left ventricular hypertrophy; PD, peritoneal dialysis.
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